• Boundless Bio outlined strategy to develop extrachromosomal DNA-directed cancer therapies targeting tumors driven by oncogene amplification, an area it estimates affects about 1.3 million new patients a year in major markets.
• Lead program BBI-940, an oral kinesin degrader, is in KOMODO-1 Phase 1 first-in-human testing, positioning it as company’s most advanced clinical asset.
• Presentation cited internal and published analyses indicating about 25% of cancer patients have amplified oncogenes, with about 54% of high-copy number amplifications occurring on ecDNA, which it linked to poorer survival.
• Pipeline also includes preclinical candidates BBI-355, an oral CHK1 inhibitor, plus BBI-825, an oral RNR inhibitor, aimed at vulnerabilities tied to ecDNA replication stress and DNA synthesis.
• Company projected cash runway into 2H28, framing it as sufficient to reach expected clinical proof of concept for BBI-940.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.